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Abstracts A41
years with an admitting diagnosis of cancer, had received chemotherapy, and were 
treated with EPO or DARB during their hospital stay. Patients were excluded if they 
had chronic kidney disease, received renal dialysis, or were treated with both ESAs. 
To minimize the effect of outliers, 2% of patients with extreme doses in each group 
were excluded from the dosing analysis. October 2008 wholesale acquisition costs
(EPO: $13.77/1000 Units, DARB: $4.818/mcg) were used to calculate ESA costs. 
RESULTS: A total of 10,733 inpatient stays were identiﬁ ed (EPO: 8,218, DARB:
2,515). EPO patients were slightly older than DARB patients (age: EPO 60.6 years, 
DARB 59.4 years, P  0.0008). Gender distribution and mean hospitalization length 
of stay (LOS) were comparable between the two groups (% women: EPO 53.7%,
DARB 52.7%; LOS in days: EPO: 13.1, DARB: 12.7; P  0.05 for both). Mean 
cumulative dose per inpatient stay was EPO 64,639 Units and DARB 309 mcg, cor-
responding to a dose ratio of 209:1 (Units EPO: mcg DARB). The corresponding 
ESA treatment cost was signiﬁ cantly lower in the EPO group, compared with DARB
(EPO: $890, DARB: $1,489; P  0.0001). Subset analysis based on 2007 dosing pat-
terns reported similar ﬁ ndings, as did sensitivity analyses using different deﬁ nitions of 
outlier doses. CONCLUSIONS: This analysis reported a dose ratio between EPO and 
DARB of 209:1 (Units EPO: mcg DARB) in cancer patients receiving chemotherapy. 
EPO was found to cost 40% less than DARB, based on the cumulative dose adminis-
tered during hospitalization despite the two groups having comparable LOS.
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OBJECTIVES: Matching has become a popular approach to estimate average treat-
ment effect. Different matching techniques provide different results. However, match-
ing cannot control for unobserved bias. Using the ProbChoice algorithm and 
Rosenbaum bounding approach, we aim to show how choosing a strongly unmeasured
variable must inﬂ uence the selection process to undermine the implication of matching
analysis. METHODS: The Surveillance, Epidemiology, and End Results (SEER) Data
is used for the analysis. The SEER-Medicare Database is created by linking Medicare 
identiﬁ ers to SEER patients aged 65 and all claims collected including hospital, physi-
cian, clinic. Patients’ hospital of care and associated hospital volume is computed.
Patients in high and low volume hospitals are matched in seven different ways for 
demographic and clinical characteristics. Treatment costs are also compared. The best 
technique is chosen by the ProbChoice algorithm. Rosenbaum bonds estimates and
Mantel and Haenszel test statistics are calculated to provide evidence on the degree 
to which any signiﬁ cance results hinge on unconfoundedness assumption. RESULTS:
A volume cohort was constructed consisting of 19,375 female SEER-Medicare
patients, aged 65, suffering an in situ and/or invasive breast cancer during 2003–2005
with surgical treatment performed at 567 hospitals. Mahalanobis matching created 
the best balanced comparable sets. After matching, samples were similar in terms of 
race, comorbidity and adjuvant therapies. Under the assumption of no hidden bias, 
costs were lower for high volume hospitals (p  0.000). Results were insensitive to a 
bias that would double the odds of being treated at high volume hospitals but sensitive 
to a bias that would triple the odds. CONCLUSIONS: Several matching techniques 
exist and results depend on the type of matching chosen. One needs to choose the
technique best suited for the data. Rosenbaum bonds provide evidence on sensitivity
of the estimated results for unobservable factors that are not controlled by propensity
score matching.
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OBJECTIVES: To quantify direct medical costs (inpatient, outpatient, pharmacy) 
of initial therapy with FDA-approved renal cell carcinoma (RCC) oral therapies
(sorafenib, sunitinib) in treatment of RCC patients who are privately insured and 
under 65 years. METHODS: Using data from MarketScan MedStat, a database 
covering all US census regions and included q18 million lives, we conducted a retro-
spective claims-based study. Between January 2002 and December 2007, patients
with q2 RCC claims (ICD-9 189.0, 198.0), continuous health care coverage, and 180 
days of coverage before RCC diagnosis and who received sorafenib or sunitinib
were eligible for inclusion. Observation period lasted from ﬁ rst drug-dispensing
date until a12 months or ﬁ rst of therapy-switch, nephrectomy, disenrollment, or
study end (December 31, 2007). Univariate and multivariate Tobit analyses were
conducted. Variables included age, sex, region, plan type, comorbidities, prior treat-
ments/procedures, and time since RCC diagnosis. RESULTS: Of 10,462 RCC patients 
identiﬁ ed, 144 received sorafenib and 220 received sunitinib as initial therapy. In the
180 days before RCC diagnosis, total direct medical costs, baseline demographics, 
and comorbidities were not statistically signiﬁ cantly different between groups. 
Univariate total monthly medical costs for the sunitinib group were statistically sig-
niﬁ cantly greater than for the sorafenib group ($9476 vs. $7426, respectively; P 
0.01), representing a yearly cost difference for sunitinib of $24,588 more than 
sorafenib. Univariate incremental monthly inpatient and pharmacy costs for sunitinib
were $861 (P  0.01) and $889 (P  0.01), respectively, and outpatient therapy was 
$300 (P  0.14) more than sorafenib. Multivariate analyses for incremental total 
monthly inpatient and pharmacy costs for sunitinib also remained signiﬁ cant at $1399,
$1259, and $689, respectively (P  0.01). CONCLUSIONS: This analysis showed
statistically signiﬁ cant cost differences, including lower total monthly medical, inpa-
tient and pharmacy costs, associated with sorafenib compared with sunitinib when
used as initial therapy in RCC patients under 65 years. Reasons for these differences
require further exploration.
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OBJECTIVES: New therapies for advanced NSCLC offering beneﬁ ts over standard 
treatment with chemotherapy should also offer value for money. Bevacizumab com-
bined with chemotherapy improves survival in patients with advanced NSCLC 
compared with chemotherapy alone. Cetuximab has shown a marginal survival 
beneﬁ t but no improvement in progression-free survival. Marketing authorization 
is anticipated in 2009. This study aimed to compare treatment costs of bevacizu-
mab-based or cetuximab-based therapy in France, Germany, Italy and Spain.
METHODS: A Markov model was used to compare drug and administration costs
associated with treating advanced NSCLC with bevacizumab-based or cetuximab-
based therapy. The model assumes patients move from non-progressive to progressed 
disease before death, according to transition probabilities of the efﬁ cacy of bevaci-
zumab-based and cetuximab-based therapy in terms of progression-free survival 
using data from the respective pivotal trials. A common post-progression survival
risk was assumed. Drug costs assumed up to 6 chemotherapy cycles, initial administra-
tion of cetuximab at 400 mg/m² followed by 250 mg/m² weekly until progression 
and that bevacizumab was administered at 7.5 mg/kg until progression. The model 
estimated average drug and administration costs (data derived from local sources) per
patient for either treatment. RESULTS: Across the four countries the average monthly 
drug cost with bevacizumab-based therapy ranged from €130 to €902 less per patient 
compared with cetuximab-based therapy. Similarly, the mean total treatment cost with 
bevacizumab-based therapy ranged from €4,713 to €12,269 less per patient compared 
with cetuximab-based therapy across the four countries. For example, in France mean 
treatment costs for bevacizumab-based and cetuximab-based therapy were €23,849 
and €35,678, respectively (a saving of €11,829 per patient with bevacizumab-based
therapy). CONCLUSIONS: Targeted therapy using bevacizumab is less costly than 
cetuximab in representative countries. Based on these results bevacizumab provides 
better value in terms of budget and outcomes in patients with advanced NSCLC.
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OBJECTIVES: Although new treatments for advanced NSCLC offer beneﬁ ts over
standard chemotherapy they should also offer value for money. Bevacizumab improves 
survival and time to progression in patients with advanced NSCLC with chemotherapy 
compared with chemotherapy alone. Pemetrexed has shown improved efﬁ cacy over 
gemcitabine for induction chemotherapy and best supportive care in maintenance and
marketing authorization is anticipated during 2009. The aim of this study was to
compare the treatment costs of bevacizumab plus cisplatin and gemcitabine (bevaci-
zumab-based therapy) with pemetrexed plus cisplatin induction and maintenance
therapy (pemetrexed-based therapy) in Germany and Italy. METHODS: A 3-state
Markov model was used to evaluate the costs of treating advanced or recurrent
NSCLC with either bevacizumab-based or pemetrexed-based therapy. The model
assumes patients move between states according to transition probabilities derived 
from the efﬁ cacy data (progression-free survival) from the pivotal trials. Drug costs
assumed chemotherapy was given for up to 4 cycles, but that single agents pemetrexed 
and bevacizumab (7.5 mg/kg) were administered until progression. RESULTS: Com-
pared with pemetrexed-based therapy, the mean monthly drug cost with bevacizumab-
based therapy was €769 less per patient in Italy. The mean monthly drug costs for 
bevacizumab-based therapy were €6455 and €6106 for pemetrexed-based therapy in 
Germany. However, the mean monthly cost of bevacizumab was always less than 
pemetrexed (€3499 vs €5871 in Germany; €2067 vs €3600 in Italy). The mean total 
treatment cost with bevacizumab-based therapy was always less than pemetrexed-
based therapy (e.g. €27530 for bevacizumab-based therapy, €33291 for pemetrexed-
based therapy in Italy). CONCLUSIONS: Triplet therapy with bevacizumab is similar 
or less costly than doublet therapy with pemetrexed. Furthermore, it is anticipated
that drug costs with bevacizumab-based therapy will reduce in 2009 when gemcitabine 
comes off patent. From a budget perspective bevacizumab should be considered as the 
targeted therapy of choice for patients with advanced NSCLC.
